Targeted therapy in chronic myeloid leukemia

Elias Jabbour, Jorge E. Cortes, Hady Ghanem, Susan O'Brien, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.

Original languageEnglish (US)
Pages (from-to)99-110
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl Fusion Proteins
Therapeutics
Philadelphia Chromosome
Mutation
Stem Cell Transplantation
Imatinib Mesylate
Protein-Tyrosine Kinases

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • Imatinib
  • Nitotinib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Targeted therapy in chronic myeloid leukemia. / Jabbour, Elias; Cortes, Jorge E.; Ghanem, Hady; O'Brien, Susan; Kantarjian, Hagop M.

In: Expert Review of Anticancer Therapy, Vol. 8, No. 1, 01.01.2008, p. 99-110.

Research output: Contribution to journalReview article

Jabbour, E, Cortes, JE, Ghanem, H, O'Brien, S & Kantarjian, HM 2008, 'Targeted therapy in chronic myeloid leukemia', Expert Review of Anticancer Therapy, vol. 8, no. 1, pp. 99-110. https://doi.org/10.1586/14737140.8.1.99
Jabbour, Elias ; Cortes, Jorge E. ; Ghanem, Hady ; O'Brien, Susan ; Kantarjian, Hagop M. / Targeted therapy in chronic myeloid leukemia. In: Expert Review of Anticancer Therapy. 2008 ; Vol. 8, No. 1. pp. 99-110.
@article{428b1b65e149419db4bf2e433f16c688,
title = "Targeted therapy in chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.",
keywords = "Chronic myeloid leukemia, Dasatinib, Imatinib, Nitotinib",
author = "Elias Jabbour and Cortes, {Jorge E.} and Hady Ghanem and Susan O'Brien and Kantarjian, {Hagop M.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1586/14737140.8.1.99",
language = "English (US)",
volume = "8",
pages = "99--110",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Targeted therapy in chronic myeloid leukemia

AU - Jabbour, Elias

AU - Cortes, Jorge E.

AU - Ghanem, Hady

AU - O'Brien, Susan

AU - Kantarjian, Hagop M.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.

AB - Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Imatinib

KW - Nitotinib

UR - http://www.scopus.com/inward/record.url?scp=38349016567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349016567&partnerID=8YFLogxK

U2 - 10.1586/14737140.8.1.99

DO - 10.1586/14737140.8.1.99

M3 - Review article

C2 - 18095887

AN - SCOPUS:38349016567

VL - 8

SP - 99

EP - 110

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -